Clinical Trial Update: PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC [Phase 2]

View source ↗

Summary

A Phase II trial evaluating panitumumab, nivolumab, and ipilimumab in Kras/NRAS/BRAF wild-type MSS metastatic colorectal cancer has completed enrollment and pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Vectibix (panitumumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Colon Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-10-22